The Uremic (Renal) Pruritus drugs in development market research report provides comprehensive information on the therapeutics under development for Uremic (Renal) Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Uremic (Renal) Pruritus. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Uremic (Renal) Pruritus and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Uremic (Renal) Pruritus by 12 companies/universities/institutes. The top development phase for Uremic (Renal) Pruritus is phase ii with three drugs in that stage. The Uremic (Renal) Pruritus pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Uremic (Renal) Pruritus pipeline products market are: Lumosa Therapeutics, Sanwa Kagaku Kenkyusho and Toray Industries.
The key targets in the Uremic (Renal) Pruritus pipeline products market include Kappa Type Opioid Receptor (KOR1 or OPRK or OPRK1), Mas Related G Protein Coupled Receptor Member X4 (Sensory Neuron Specific G Protein Coupled Receptor 5/6 or MRGPRX4), and Mu Type Opioid Receptor (MOR1 or Mu Opiate Receptor or Mu Opioid Receptor or OPRM1).
The key mechanisms of action in the Uremic (Renal) Pruritus pipeline product include Kappa Type Opioid Receptor (KOR1 or OPRK or OPRK1) Agonist with five drugs in Pre-Registration. The Uremic (Renal) Pruritus pipeline products include five routes of administration with the top ROA being Oral and four key molecule types in the Uremic (Renal) Pruritus pipeline products market including Small Molecule, and Synthetic Peptide.
Uremic (Renal) Pruritus overview
Uremic pruritis is a condition where there is presence of excess urea in the blood associated with itchiness (pruritis). It is associated with chronic kidney disease (CKD). Most common in end stage CKD and patients on hemodialysis. Underlying diseases (CKD), diabetes, inflammation, uremic toxins are common triggering factors affecting 20-25% of body surface area and is associated with itchiness, secondary skin changes like eczema, lichen simplex, dry skin, triggered when exposed to sun, radiation etc. Diagnosed by skin biopsy, blood and urine analysis to find out the levels of urea, GFR rate, and differential diagnosis. Topical therapies like topical analgesics, emollients, tacrolimus to suppress the production of interleukins, antihistamines to treat itchiness, opioid agonist and antagonist, phototherapy and in complicated cases renal transplantation chosen.
For a complete picture of Uremic (Renal) Pruritus’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
